Abstract:and Ն9%, respectively. Compared with placebo, more patients achieved HbA1c Ͻ7% (39.4% vs 24.4%) and Ͻ8% (79.5% vs 60.6%) and fewer patients remained at or worsened to HbA1c Ͼ9% (4.2% vs 13.9%) with dapagliflozin. CONCLUSIONS: Dapagliflozin 10 mg/day reduced HbA1c across all baseline HbA1c categories; greater reductions were seen in patients with higher baseline HbA1c. Substantially more patients attained HEDIS HbA1c categories of Ͻ7% and Ͻ8% and substantially fewer patients remained at or worsened to HbA1c Ͼ9%… Show more
scite is a Brooklyn-based startup that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.